USE OF AGONISTS IN KEY RECEPTORS FOR THE TREATMENT OF DEPRESSION AND ANXIETY

Description

In recent years, the dentate gyrus of the hippocampus has been studied as a key area of the brain involved in certain psychic disorders. The role of neuropeptides and their receptors in this region is key to finding new antidepressant treatments. In previous research, receptors in the NPY system have been shown to be attractive therapeutic targets for controlling depressive behaviors. On the other hand, the three Galanin receptors (GALR) have also been involved in behaviors related to depression, with a different role depending on the GALR subtype. Our studies on the dentate gyrus show how the GALR2 / NPYY1R heterodimer complex shows an antidepressant and anxiolytic role. In the invention, GALR2 agonists and NPYY1R agonists and their combined form are proposed as treatment to promote the GALR2 / NPYY1R interaction, as treatment and / or prevention of depression and anxiety.

Advantages

The main advantages found in this invention are: - Conventional treatments with the use of NPY agonists are improved thanks to the combined use of GALR2 agonists as they increase the antidepressant effects of NPY. - It has also been seen that these drugs that promote the GALR2 / NPYY1R interaction could be used for both depression and anxiety symptoms, psychic disorders that are usually found together in the patient.

Uses and Applications

Pharmaceutical sector. Applications in the treatment of mental disorders (depression and anxiety).

Keywords

Sectors

Areas

Patent Number

ES2589165B2  Expediente

Applicants

Universidad De Málaga

Inventors

Manuel Alejandro Narvaez Pelaez, Carmelo Millón Peñuela, Belen Gago Calderon, Antonio Flores Burgess, Luis Javier Santin Nuñez, Jose Angel Narvaez Bueno, Maria Zaida Diaz Cabiale

Filing Date

20/11/2015 

Protection Level: National (Spain)

Processing Status: Spanish patent